Pulmonary Hypertension in COPD: A Case Study and Review of the Literature

Overview

Journal Medicina (Kaunas)

Publisher MDPI

Specialty General Medicine

Date 2019 Aug 7

PMID 31382489

Citations 7

Authors

Steven J Cassady

Robert M Reed

Affiliations

Soon will be listed here.

Abstract

Pulmonary hypertension (PH) is a frequently encountered complication of chronic obstructive pulmonary disease (COPD) and is associated with worsened clinical symptoms and prognosis. The prevalence of PH-COPD is not concretely established as classification criteria vary historically, but the presence of severe disease out of proportion to underlying COPD is relatively rare. Right heart catheterization, the gold standard in diagnosis of PH, is infrequently performed in COPD, and the overlap in the clinical symptoms of PH and COPD presents diagnostic challenges. Proven treatments are limited. Trials exploring the use of vasodilator therapy in this patient group generally demonstrate improvements in hemodynamics accompanied by worsening gas exchange without clearly demonstrated improvements in clinically meaningful outcomes. In-depth workup of underlying pulmonary hypertension and use of pulmonary vasodilator medications may be appropriate on an individual basis. We present a case study and a review and discussion of the pertinent literature on this topic.

Citing Articles

Sense of loneliness and meaning in life in chronic obstructive pulmonary disease patients. Preliminary studies.

Sipowicz K, Pietras T, Sobstyl M, Mosiolek A, Rozycka-Kosmalska M, Mosiolek J Multidiscip Respir Med. 2024; 19.

PMID: 39530889 PMC: 11614002. DOI: 10.5826/mrm.2024.994.

Risk factors for renal progression in patients with CKD and coexisting COPD.

Zhu F, Gan W, Liu H, Chen W, Zeng X Int Urol Nephrol. 2024; 57(3):885-895.

PMID: 39400674 DOI: 10.1007/s11255-024-04227-x.

Novelty of Physiotherapy Management in a Classic Case of Chronic Obstructive Pulmonary Disease in an 84-Year-Old Male Patient with Hypertension and Well-Controlled Hypothyroidism: A Case Report.

Nangliya R, Yadav V, Nandanwar S Cureus. 2024; 16(3):e57318.

PMID: 38690482 PMC: 11060019. DOI: 10.7759/cureus.57318.

G6PD is a prognostic biomarker correlated with immune infiltrates in lung adenocarcinoma and pulmonary arterial hypertension.

Ding R, Sang S, Yi J, Xie H, Wang F, Dai A Aging (Albany NY). 2024; 16(1):466-492.

PMID: 38194707 PMC: 10817399. DOI: 10.18632/aging.205381.

Periodontitis contributes to COPD progression via affecting ferroptosis.

Xiong K, Yang P, Wei W, Li J, Cui Y, Li Y BMC Oral Health. 2023; 23(1):664.

PMID: 37710216 PMC: 10500905. DOI: 10.1186/s12903-023-03397-x.

References

Bajwa A, Shujaat A, Patel M, Thomas C, Rahaghi F, Burger C . The safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension and chronic obstructive pulmonary disease. Pulm Circ. 2017; 7(1):82-88. PMC: 5448530. DOI: 10.1086/689291. View

Awerbach J, Stackhouse K, Lee J, Dahhan T, Parikh K, Krasuski R . Outcomes of lung disease-associated pulmonary hypertension and impact of elevated pulmonary vascular resistance. Respir Med. 2019; 150:126-130. DOI: 10.1016/j.rmed.2019.03.004. View

Olsson K, Hoeper M, Pausch C, Grunig E, Huscher D, Pittrow D . Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry. Eur Respir J. 2021; 58(2). DOI: 10.1183/13993003.01483-2021. View

Simonneau G, Montani D, Celermajer D, Denton C, Gatzoulis M, Krowka M . Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2018; 53(1). PMC: 6351336. DOI: 10.1183/13993003.01913-2018. View

Wells J, Washko G, Han M, Abbas N, Nath H, Mamary A . Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med. 2012; 367(10):913-21. PMC: 3690810. DOI: 10.1056/NEJMoa1203830. View

Vitulo P, Stanziola A, Confalonieri M, Libertucci D, Oggionni T, Rottoli P . Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial. J Heart Lung Transplant. 2016; 36(2):166-174. DOI: 10.1016/j.healun.2016.04.010. View

Seeger W, Adir Y, Barbera J, Champion H, Coghlan J, Cottin V . Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013; 62(25 Suppl):D109-16. DOI: 10.1016/j.jacc.2013.10.036. View

Chaouat A, Bugnet A, Kadaoui N, Schott R, Enache I, Ducolone A . Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005; 172(2):189-94. DOI: 10.1164/rccm.200401-006OC. View

Timms R, Khaja F, Williams G . Hemodynamic response to oxygen therapy in chronic obstructive pulmonary disease. Ann Intern Med. 1985; 102(1):29-36. DOI: 10.7326/0003-4819-102-1-29. View

10.

Arcasoy S, Christie J, Ferrari V, St John Sutton M, Zisman D, Blumenthal N . Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med. 2002; 167(5):735-40. DOI: 10.1164/rccm.200210-1130OC. View

11.

Wrobel J, McLean C, Thompson B, Stuart-Andrews C, Paul E, Snell G . Pulmonary arterial remodeling in chronic obstructive pulmonary disease is lobe dependent. Pulm Circ. 2014; 3(3):665-74. PMC: 4070801. DOI: 10.1086/674339. View

12.

Scharf S, Iqbal M, Keller C, Criner G, Lee S, Fessler H . Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med. 2002; 166(3):314-22. DOI: 10.1164/rccm.2107027. View

13.

Giaid A, Yanagisawa M, Langleben D, Michel R, Levy R, Shennib H . Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993; 328(24):1732-9. DOI: 10.1056/NEJM199306173282402. View

14.

Kessler R, Faller M, Weitzenblum E, Chaouat A, Aykut A, Ducolone A . "Natural history" of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med. 2001; 164(2):219-24. DOI: 10.1164/ajrccm.164.2.2006129. View

15.

Giaid A, Saleh D . Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995; 333(4):214-21. DOI: 10.1056/NEJM199507273330403. View

16.

Hoeper M, Vonk-Noordegraaf A . Is there a vanishing pulmonary capillary syndrome?. Lancet Respir Med. 2017; 5(9):676-678. DOI: 10.1016/S2213-2600(17)30291-6. View

17.

Santos S, Peinado V, Ramirez J, Melgosa T, Roca J, Rodriguez-Roisin R . Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J. 2002; 19(4):632-8. DOI: 10.1183/09031936.02.00245902. View

18.

Stolz D, Rasch H, Linka A, Di Valentino M, Meyer A, Brutsche M . A randomised, controlled trial of bosentan in severe COPD. Eur Respir J. 2008; 32(3):619-28. DOI: 10.1183/09031936.00011308. View

19.

Hoffmann J, Wilhelm J, Olschewski A, Kwapiszewska G . Microarray analysis in pulmonary hypertension. Eur Respir J. 2016; 48(1):229-41. PMC: 5009873. DOI: 10.1183/13993003.02030-2015. View

20.

Wang L, Jin Y, Zhao Q, Jiang R, Wu W, Gong S . Hemodynamic and gas exchange effects of inhaled iloprost in patients with COPD and pulmonary hypertension. Int J Chron Obstruct Pulmon Dis. 2017; 12:3353-3360. PMC: 5702173. DOI: 10.2147/COPD.S141798. View